Table 1.

Details of some factors of T cells that predict responses to immune checkpoint inhibitor therapy. MM (malignant melanoma), GC (gastric cancer), NSCLC (non-small lung cancer), burned-out CD8⁺ TIL (Ebo subset).

Type of Marker	Marker	Association with Response to Treatment	Cancer Type	References
T cell biomarkers of the periphery	CD27−	negative	MM	Moreira et al. [111]
	CD28−	negative	NSCLC, MM	Moreira et al. [111]; Ferrara et al. [112]
	CD-57+	negative	MM	Moreira et al. [111]
	TIM-3+	negative	MM	Moreira et al. [111]
	KLRG1+	negative	NSCLC	Ferrara et al. [112]
	Cytotoxic activity	positive	NSCLC	Iwahori et al. [113]
T cell biomarkers of the TME	TCF7	positive	MM	Sade-Feldman et al. [116]
	T cell inflamed GEP	positive	multiple cancer types	Christescu et al. [117]; Olson et al. [118]; Ayers et al. [119]
	Ebo subset	negative	NSCLC	Sanmamed [120]
	CXCL13	positive	multiple cancer types	Thommen et al. [121]; Litchfield et al. [122]
	CCR5	positive	multiple cancer types	Litchfield et al. [122]
	PD-1+	positive	MM, GC, NSCLC	Kumagai et al. [123]